Abstract
Early revascularization with percutaneous coronary intervention or coronary artery bypass grafting has been proven as beneficial for survival in patients with myocardial infarction complicated by cardiogenic shock. This review focuses on technical aspects of coronary revascularization and additive medication. One of the most important actual questions in intervention in cardiogenic shock is the decision to perform culprit lesion only or multi-vessel percutaneous coronary intervention in patients with multivessel coronary artery disease. A large randomized study is currently enrolling patients to answer this question.
